Posters

Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine receptor blocking agents. Long-term safety of the approved TD medication, valbenazine, was demonstrated in 2 clinical trials (KINECT 3 [NCT02274558], KINECT 4 [NCT02405091]). Data from these trials were analyzed post hoc to evaluate the onset and resolution of adverse events (AEs).

This study sought to understand the evolving continuing medical education (CME) needs of physicians managing patients with tardive dyskinesia (TD). A case-based survey was developed, and later updated, to assess current practice, knowledge, and attitudes of neurologists and psychiatrists in the management of patients with TD.

Best practices in Tardive Dyskinesia (TD) identification and management among psychiatry and neurology clinicians have historically been suboptimal. The gaps in practice include a lack of awareness of TD coupled with not routinely utilizing diagnostic tools for the monitoring and assessment of at-risk patient populations.

Geriatric populations are at increased risk of developing tardive dyskinesia as they age, leading to increased risk of injuries secondary to resulting impairments in gait and balance. VMAT2 inhibitors such as valbenazine, deutetrabenazine, and tetrabenazine are the first-line treatment for control of tardive dyskinesia symptoms.

Tardive dyskinesia (TD) is associated with antipsychotic (AP) use Deutetrabenazine (DTBZ) is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) approved to treat TD.